
FDA accelerated approval speeds access but faces challenges with trial completion, costs, and end point validation.

FDA accelerated approval speeds access but faces challenges with trial completion, costs, and end point validation.

Health systems must have a flexible workflow in place to allow the use of non-preferred agents to accommodate payer demands and reduce financial toxicity.